Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N T Clausen

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|May 1, 1987
Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapyL Specht, A M Nordentoft, S Cold, et al.
Cancer|April 15, 1988
Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatmentL Specht, A M Nordentoft, S Cold, et al.
Clinical and Laboratory Haematology|October 16, 2004
Anagrelide treatment in 52 patients with chronic myeloproliferative diseasesE Penninga, B A Jensen, P B Hansen, et al.
International Journal of Laboratory Hematology|March 31, 2016
Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translationN E U Hermansen, R Borup, M K Andersen, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|May 1, 1987
Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapyL Specht, A M Nordentoft, S Cold, et al.
Cancer|April 15, 1988
Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatmentL Specht, A M Nordentoft, S Cold, et al.
Clinical and Laboratory Haematology|October 16, 2004
Anagrelide treatment in 52 patients with chronic myeloproliferative diseasesE Penninga, B A Jensen, P B Hansen, et al.
International Journal of Laboratory Hematology|March 31, 2016
Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translationN E U Hermansen, R Borup, M K Andersen, et al.
Pageof 2